Please assess the completion status of the following clinical trial:

Trial Title: Study of Albumin to Reduce Inflammation Following Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients over sixteen years of age undergoing surgery that requires cardiopulmonary bypass who provide informed written consent~Exclusion Criteria:~* Lack of informed consent~* Pregnancy~* Cyanotic congenital heart disease (due to high haemoglobin levels and increased haemolysis)~* Patients undergoing other extracorporeal interventions (ventricular assist devices, extracorporeal membrane oxygenators, pre-admission dialysis)~* Patients with congenital haemoglobinopathies (e.g. thalassaemia, cryoglobinuria, etc)~* Patients with disorders of iron metabolism (e.g. haemochromatosis)~* Religious objections to transfusion of a plasma-derived product~* Patients with known blood borne infection~* Patients with known hypersensitivity to gelofusine or human albumin solution~* Patients with an additive EUROSCORE of 10 or more

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 Albumin (Type: EXPERIMENTAL): Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
- 2 Gelofusin (Type: PLACEBO_COMPARATOR): Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).